Immunotherapy News and Research

Latest Immunotherapy News and Research

NCCN releases new resources to improve quality of life for people with cancer

NCCN releases new resources to improve quality of life for people with cancer

Redefining the battle against Alzheimer's with tau-focused treatments

Redefining the battle against Alzheimer's with tau-focused treatments

Study offers the most comprehensive look to date on prostate cancer disparities

Study offers the most comprehensive look to date on prostate cancer disparities

New ERC-funded research project aims to develop targeted treatments for chronic wounds and cancer

New ERC-funded research project aims to develop targeted treatments for chronic wounds and cancer

Microbubble-based biomarker could improve NIR-PIT treatment for cancer

Microbubble-based biomarker could improve NIR-PIT treatment for cancer

UTHSC researcher part of team studying obesity-cancer connection

UTHSC researcher part of team studying obesity-cancer connection

Immunologists aim to explore new avenues for immunotherapy of liver metastases

Immunologists aim to explore new avenues for immunotherapy of liver metastases

New bioreactor could accelerate access to cancer-killing immunotherapy

New bioreactor could accelerate access to cancer-killing immunotherapy

Researchers receive €10.6 million to develop new therapeutic approaches to target glioblastoma

Researchers receive €10.6 million to develop new therapeutic approaches to target glioblastoma

Could the microbiome hold the key to diagnosing and treating biliary tract cancer?

Could the microbiome hold the key to diagnosing and treating biliary tract cancer?

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

Researchers discover new way to trigger programmed cell death in cancer cells

Researchers discover new way to trigger programmed cell death in cancer cells

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

Utilizing Biomarkers in Cancer Prevention, Diagnosis, and Treatment

Utilizing Biomarkers in Cancer Prevention, Diagnosis, and Treatment

Chemotherapy plus immunotherapy improves survival in patients with metastatic urothelial cancer

Chemotherapy plus immunotherapy improves survival in patients with metastatic urothelial cancer

Perioperative immunotherapy improves event-free survival in resectable early-stage lung cancer

Perioperative immunotherapy improves event-free survival in resectable early-stage lung cancer

New method uses extracellular vesicles to enhance immunotherapy responses in glioblastoma

New method uses extracellular vesicles to enhance immunotherapy responses in glioblastoma

Collaborative team receives NCI grant to study how to improve immunotherapy for diffuse midline gliomas

Collaborative team receives NCI grant to study how to improve immunotherapy for diffuse midline gliomas

"Two-for-one" cancer immunotherapy more effective and at least as safe as standard treatments

"Two-for-one" cancer immunotherapy more effective and at least as safe as standard treatments

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.